Imperial College London
Portrait Picture

DrChristopherRhodes

Faculty of Medicine, National Heart & Lung Institute

Reader in Pulmonary Vascular Disease
 
 
 
//

Contact

 

+44 (0)20 7594 7638c.rhodes07

 
 
//

Location

 

535ICTEM buildingHammersmith Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Oldham:2021:10.1016/j.jacc.2021.02.056,
author = {Oldham, WM and Hemnes, AR and Aldred, MA and Barnard, J and Brittain, EL and Chan, SY and Cheng, F and Cho, MH and Desai, AA and Garcia, JGN and Geraci, MW and Ghiassian, SD and Hall, KT and Horn, EM and Jain, M and Kelly, RS and Leopold, JA and Lindstrom, S and Modena, BD and Nichols, WC and Rhodes, CJ and Sun, W and Sweatt, AJ and Vanderpool, RR and Wilkins, MR and Wilmot, B and Zamanian, RT and Fessel, JP and Aggarwal, NR and Loscalzo, J and Xiao, L},
doi = {10.1016/j.jacc.2021.02.056},
journal = {Journal of the American College of Cardiology},
pages = {2040--2052},
title = {NHLBI-CMREF workshop report on pulmonary vascular disease classification: JACC state-of-the-art review.},
url = {http://dx.doi.org/10.1016/j.jacc.2021.02.056},
volume = {77},
year = {2021}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - The National Heart, Lung, and Blood Institute and the Cardiovascular Medical Research and Education Fund held a workshop on the application of pulmonary vascular disease omics data to the understanding, prevention, and treatment of pulmonary vascular disease. Experts in pulmonary vascular disease, omics, and data analytics met to identify knowledge gaps and formulate ideas for future research priorities in pulmonary vascular disease in line with National Heart, Lung, and Blood Institute Strategic Vision goals. The group identified opportunities to develop analytic approaches to multiomic datasets, to identify molecular pathways in pulmonary vascular disease pathobiology, and to link novel phenotypes to meaningful clinical outcomes. The committee suggested support for interdisciplinary research teams to develop and validate analytic methods, a national effort to coordinate biosamples and data, a consortium of preclinical investigators to expedite target evaluation and drug development, longitudinal assessment of molecular biomarkers in clinical trials, and a task force to develop a master clinical trials protocol for pulmonary vascular disease.
AU  - Oldham,WM
AU  - Hemnes,AR
AU  - Aldred,MA
AU  - Barnard,J
AU  - Brittain,EL
AU  - Chan,SY
AU  - Cheng,F
AU  - Cho,MH
AU  - Desai,AA
AU  - Garcia,JGN
AU  - Geraci,MW
AU  - Ghiassian,SD
AU  - Hall,KT
AU  - Horn,EM
AU  - Jain,M
AU  - Kelly,RS
AU  - Leopold,JA
AU  - Lindstrom,S
AU  - Modena,BD
AU  - Nichols,WC
AU  - Rhodes,CJ
AU  - Sun,W
AU  - Sweatt,AJ
AU  - Vanderpool,RR
AU  - Wilkins,MR
AU  - Wilmot,B
AU  - Zamanian,RT
AU  - Fessel,JP
AU  - Aggarwal,NR
AU  - Loscalzo,J
AU  - Xiao,L
DO  - 10.1016/j.jacc.2021.02.056
EP  - 2052
PY  - 2021///
SN  - 0735-1097
SP  - 2040
TI  - NHLBI-CMREF workshop report on pulmonary vascular disease classification: JACC state-of-the-art review.
T2  - Journal of the American College of Cardiology
UR  - http://dx.doi.org/10.1016/j.jacc.2021.02.056
UR  - https://www.ncbi.nlm.nih.gov/pubmed/33888254
UR  - https://www.sciencedirect.com/science/article/pii/S0735109721005660?via%3Dihub
UR  - http://hdl.handle.net/10044/1/88342
VL  - 77
ER  -
Download